Innovative Pipeline Ocera Therapeutics is developing OCR-002, a novel ammonia scavenger targeting hepatic encephalopathy, with ongoing Phase 2b and Phase 2a trials. This indicates potential opportunities in collaborations or supply for neurohepatic and liver disease treatment markets.

Recent Acquisition Mallinckrodt acquired Ocera for up to 117 million dollars, signaling a strategic expansion into treatments for orphan and liver diseases. Companies in related rare disease spaces may find partnership or acquisition opportunities for complementary assets.

Market Focus With Orphan Drug designation and Fast Track status from the FDA, Ocera’s focus on high unmet medical needs presents a pathway for healthcare providers and payers seeking innovative therapies for serious conditions.

Small but Strategic As a clinical-stage firm with 11-50 employees and revenue between one to ten million dollars, Ocera offers a potentially agile partner for niche biotech collaborations or licensing agreements.

Technology & Data Ocera’s website utilizes modern web technologies and analytics tools, indicating an emphasis on digital engagement and data-driven decision making, which could be leveraged for collaborative marketing or patient outreach strategies.